Publications by authors named "Gaston Martinengo"
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
September 2024
Article Synopsis
- The KEYNOTE-671 trial showed that adding pembrolizumab to neoadjuvant chemotherapy significantly enhanced event-free survival in patients with early-stage non-small-cell lung cancer (NSCLC).
- The trial involved randomizing nearly 800 participants across 189 medical centers, comparing treatment with pembrolizumab plus chemotherapy against a placebo plus chemotherapy.
- Results indicated that after 36 months, overall survival was higher in the pembrolizumab group (71%) compared to the placebo group (64%), suggesting a positive impact of the immunotherapy.
Background: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone.
Methods: We conducted a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab in patients with early-stage NSCLC. Participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned in a 1:1 ratio to receive neoadjuvant pembrolizumab (200 mg) or placebo once every 3 weeks, each of which was given with cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every 3 weeks for up to 13 cycles.
Background: Nivolumab was the first anti-programmed cell death 1 drug approved in Argentina for non-small-cell lung cancer treatment in the second-line setting.
Materials And Methods: The present study was a multicenter, observational, retrospective study of patients with progression to stage IV NSCLC during platinum-based chemotherapy who had received nivolumab monotherapy in a drug-expanded access program in Argentina.
Results: The data from 109 patients were assessed retrospectively for safety and clinical outcomes.